Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcgammaRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for FcgammaRIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan(R)), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan(R)), are also provided. The methods of the present invention find use in treatment of inflammatory diseases and autoimmune diseases that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to inflammatory diseases and autoimmune diseases that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having an inflammatory or autoimmune disease that is non-responsive or refractory to therapy with other therapeutic agents such as anti-CD20 antibodies.본 발명은 인간 환자의 CD40-발현 세포와 관련된 염증 질환 또는 자가면역 질환의 치료 방법을 제공하며, 인간 환자는 FcγRIIIa-158F에 대하여 이종접합 또는 동종접합(유전형 V/F 또는 F/F)이다. 또한 FcγRIIIa-158F에 대하여 이종접합 또는 동종접합(유전형 V/F 또는 F/F)인 인간 환자 내의 B 세포에 의한 항체 생산 억제 방법을 제공한다. 본 방법은 인간 환자에게 항-CD40 항체의 치료적 또는 예방적 유효량을 투여하는 것을 포함한다. 항-CD40 항체로 치료가능한 염증 질환 또는 자가면역 질환을 보유하며, 리툭시맙(Rituxan®)의 치료에 미반응 또는 내성인 인간 환자를 확인하는 방법 및 키트, 및 염증 질환 또는 자가면역 질환을 보유하며, 리툭시맙(Rituxan®)의 치료에 미반응 또는 내성인 인간 환자의 치료용 항체 요법을 선택하는 방법 및 키트를 제공한다. 본 발명의 방법은 CD40-발현 세포와 관
